IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study
Inmagene Biopharmaceuticals announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants.
Uncategorized
Ossium Health Awarded $3.46M in Funding from the California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD)
Ossium Health, Inc. announced that the California Institute of Regenerative Medicine has awarded the company a $3.46M Clinical Stage Research Program grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease.
¿Por que oímos a veces un sonido agudo?
En este Short averiguaremos de dónde procede el sonido agudo o zumbido que en ocasiones oímos. …
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
Nicox SA announced that the New Drug Application for approval to commercialize ZERVIATE®, 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of National Medical Products Administration of the People’s Republic of China.
FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
Otsuka America Pharmaceutical, Inc. and Lundbeck announce the U.S. Food and Drug Administration has approved the New Drug Application for ABILIFY ASIMTUFII® extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.
Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders
Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research Dr. Mark Fishman, announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders.
Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders Read More »
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
Daewoong Pharmaceutical announced that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28.
Hillstream BioPharma Announces Pricing of Public Offering – April 28, 2023
Hillstream BioPharma, Inc. announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock.
Hillstream BioPharma Announces Pricing of Public Offering – April 28, 2023 Read More »
Appendix 4C Quarterly Activity ReportMesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2023.